Valneva Appoints Peter Buhler as Chief Financial Officer
29 Juli 2021 - 7:00AM
Saint-Herblain
(France), July
29, 2021 – Valneva SE (Nasdaq:
VALN; Euronext Paris: VLA), a specialty vaccine company focused on
the development and commercialization of prophylactic vaccines for
infectious diseases with significant unmet medical need, today
announced the appointment of Peter Buhler as Chief Financial
Officer (CFO) and Management Board member.
Peter has over 20 years of experience in the
strategic and financial leadership of life science and technology
companies. He currently serves as Chief Financial Officer of
Nasdaq-listed Swiss diagnostics company Quotient, where he
strengthened the balance sheet, raising close to $200 million in
cash. Prior to Quotient, Peter served as Group CFO of Zaluvida AG
and as Group CFO of Stallergenes Greer Plc, where he led a complex
merger project to combine a French and US Company. Prior to this,
Peter held senior finance roles at Eli Lilly, Merck Serono and
Logitech. Peter is a Swiss Certified Accountant and holds an
Executive MBA from the SBS Swiss Business School.
To ensure business continuity and transition,
David Lawrence, Acting CFO of Valneva, has agreed to continue
supporting Valneva until late 2021. It is expected that Peter will
be joining Valneva within the next six months.
Thomas
Lingelbach,
Chief
Executive
Officer of Valneva, said, “We are
delighted that Peter will join Valneva. With his proven expertise
in financial and strategic management and, most notably, his U.S.
and Nasdaq experience, he will be a great addition to our
Management Team. I would also like to thank David for his ongoing
commitment, continuous dedication and major contribution in his
current transitional role as acting CFO.”
Peter Buhler stated, “I look
forward to joining Valneva’s Management Board and leading its
finance organization to contribute to Valneva’s future success as
the company progresses to the next stage of its strategy.”
About Valneva SEValneva is a
specialty vaccine company focused on the development and
commercialization of prophylactic vaccines for infectious diseases
with significant unmet medical need. The Company takes a highly
specialized and targeted approach to vaccine development, beginning
with the identification of deadly and debilitating infectious
diseases that lack a prophylactic vaccine solution and for which
there are limited therapeutic treatment options. It then applies
its deep understanding of vaccine science, including its expertise
across multiple vaccine modalities, as well as its established
vaccine development capabilities, to develop prophylactic vaccines
to address these diseases. The Company has leveraged its expertise
and capabilities both to successfully commercialize two vaccines
and to rapidly advance a broad range of vaccine candidates into and
through the clinic, including candidates against Lyme disease, the
chikungunya virus and COVID-19.
Media
& Investor ContactsLaëtitia Bachelot-FontaineVP Global
Communications & European Investor RelationsM +33 (0)6 4516
7099
laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
- 2021_07_29_VLA_CFO_PR_EN_Final